ENDRA Life Sciences (NDRA) Total Liabilities (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Total Liabilities for 11 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 16.48% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 16.48% YoY), while the FY2025 annual figure was $1.6 million, down 15.77% from the prior year.
• Total Liabilities rose to $1.7 million in Q1 2026 per NDRA's latest filing, from $1.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $2.4 million in Q3 2023 and bottomed at $1.1 million in Q4 2023.
• Historically, Total Liabilities has averaged $1.8 million across 5 years, with a median of $1.8 million in 2025.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 78.48% — and 2023, when it slumped 47.08%.
• ENDRA Life Sciences' Total Liabilities stood at $2.1 million in 2022, then sank by 47.08% to $1.1 million in 2023, then soared by 72.76% to $1.9 million in 2024, then slipped by 15.77% to $1.6 million in 2025, then grew by 3.62% to $1.7 million in 2026.
• Business Quant data shows NDRA's Total Liabilities at $1.7 million in Q1 2026, $1.6 million in Q4 2025, and $1.8 million in Q3 2025.